## SOLV: Solventum Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -3.2% below STRENGTH zone (4.0-10.0%); PEG 1.56 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-10.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($76.07)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Solventum Corp. stock falls Tuesday, underperforms market**
- Source: MarketWatch | 20251209T210835 | Neutral | Relevance: 98%
- Solventum Corp. (SOLV) saw its stock price drop by 3.01% to $80.11 on Tuesday, underperforming the broader market. The S&P 500 Index and Dow Jones Industrial Average also experienced declines, making it the second consecutive day of losses for Solventum Corp.

**2. Solventum Corp. stock falls Tuesday, underperforms market**
- Source: MSN | 20251209T215115 | Neutral | Relevance: 98%
- This article reports that Solventum Corp. (SOLV) stock experienced a decline on Tuesday, underperforming the broader market. The stock fell by 1.94%, closing at $62.62, while the S&P 500 saw a gain. This performance comes as the stock had previously achieved a 52-week high, with the recent decline placing it below its 50-day moving average.

**3. Solventum Corp. stock falls Tuesday, underperforms market**
- Source: MarketWatch | 20251209T210835 | Neutral | Relevance: 97%
-  Solventum Corp. (SOLV) saw its stock fall by 3.01% on Tuesday, closing at $80.11. This decline occurred during a generally negative trading session where the S&P 500 Index dropped 0.09% and the Dow Jones Industrial Average fell 0.38%. This marks the second consecutive day of losses for Solventum Corp.

**4. Solventum Corporation (SOLV): A Bull Case Theory**
- Source: Finviz | 20251209T200815 | Bullish | Relevance: 97%
- This article summarizes a bull thesis on Solventum Corporation (SOLV), a healthcare company recently spun off from 3M. Despite initial high debt, the company has deleveraged significantly through asset sales and is now positioned for a turnaround under strong leadership. The thesis highlights attractive valuation, clear growth targets, and a favorable risk-reward profile for patient investors, while acknowledging risks like potential PFAS litigation.

**5. Solventum Corp. stock falls Tuesday, underperforms market**
- Source: MarketWatch | 20251209T213215 | Neutral | Relevance: 97%
-  Solventum Corp. (SOLV) shares declined by 3.01% on Tuesday, closing at $80.11. This underperformance occurred during a broader market downturn where the S&P 500 Index fell 0.09% and the Dow Jones Industrial Average fell 0.38%. This marks the second consecutive day of losses for Solventum Corp.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | BTIG | $100 | $0 | 0% |
| 2025-11-10 | UBS | $79 | $77 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | BTIG | up | Buy |
| 2025-11-10 | UBS | main | Neutral |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 0 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+5.3%)
- Independent Franchis: 7.4% (+27.2%)
- Blackrock Inc.: 5.9% (+6.1%)
- Trian Fund Managemen: 4.9% (0.0%)
- State Street Corpora: 3.6% (+1.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-10.2% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.56 elevated, pricing in significant growth expectations. Forward P/E 12.6x stretched relative to 5% growth. Quality metrics strong (ROE 37%, margin 18%). Institutional flow bullish (8 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $13.9B |
| Beta | 1.00 |
| 52W Range | $60.70 - $88.20 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.56 |
| Forward P/E | 12.6 |
| Current P/E | 13.3 |
| YoY Growth | 5.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 6.9% to -3.2% (-10.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.2pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.09x) but short-term weakness (below SMA20). RSI neutral at 52.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.25% (CS: 33) | Weak |
| RSI_14 | 51.5 | Neutral |
| MACD Histogram | -0.34 | Bearish |
| vs SMA20 | 0.988x | Below |
| vs SMA50 | 1.065x | Above |
| vs SMA200 | 1.091x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $80.11
- **Stop Loss:** $76.07 (5.0% risk)
- **Target:** $84.15 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 74
- **Position Value:** $5,928.14
- **Portfolio %:** 5.93%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-26 (Est: $1.49)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.43 | $1.50 | +4.7% |
| 2025Q2 | $1.45 | $1.69 | +16.2% |
| 2025Q1 | $1.22 | $1.34 | +9.7% |
| 2024Q4 | $1.31 | $1.41 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*